# GM-CSF With Post-Transplant Cyclophosphamide

> **NCT04237623** · PHASE2 · RECRUITING · sponsor: **Northside Hospital, Inc.** · enrollment: 38 (estimated)

## Conditions studied

- Transplant-Related Hematologic Malignancy

## Interventions

- **DRUG:** Sargramostim
- **OTHER:** Control Arm

## Key facts

- **NCT ID:** NCT04237623
- **Lead sponsor:** Northside Hospital, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-05-18
- **Primary completion:** 2026-09-18
- **Final completion:** 2026-09-18
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04237623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04237623, "GM-CSF With Post-Transplant Cyclophosphamide". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04237623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*